Targeting Tau protein novel PET imaging agent and preparation method thereof

By designing the 18F nuclide-labeled toluenezimidazolopyridine derivative [18F]FENPBM, the existing Tau-targeted PET tracer selection and insufficient penetration of cerebrovascular barriers were solved, achieving high specificity and high Affinity Tau protein PET imaging is suitable for the diagnosis and research of neurological diseases.

CN118955498AInactive Publication Date: 2024-11-15ZHEJIANG UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411005166.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Tau-targeted PET tracers have problems such as low selectivity, poor penetration of cerebrovascular barriers and poor metabolic stability, which limits their wide application in clinical practice.

Method used

Design and prepared the 18F nuclide-labeled toluenezimidazolopyridine derivative [18F]FENPBM, which has high affinity and selective targeting of Tau proteins, and achieves high stability and good blood-brain barrier penetration through an optimized radiosynthesis route. Permeability.

Benefits of technology

High specificity and high affinity Tau protein PET imaging is achieved, suitable for the diagnosis and research of neurological diseases, and provides key imaging information for early diagnosis and disease progress monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955498A_ABST
    Figure CN118955498A_ABST
Patent Text Reader

Abstract

The invention discloses a novel PET (Polyethylene Terephthalate) imaging agent for targeting Tau protein and a preparation method of the novel PET imaging agent, and the novel PET imaging agent is recorded as [18F] FENPBM and has the following structural formula; the compound can be used as a positron emission tomography (PET) tracer, can be combined with Tau protein with high specificity in a living body, provides key image information in the aspects of early diagnosis, disease progress monitoring, curative effect evaluation, pathological research and the like, and has wide clinical and research application prospects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the development and preparation of a novel radioactive drug, belonging to the field of nuclear medicine technology, and relates to a novel PET imaging agent targeting Tau protein and a preparation method thereof. Background Art

[0002] Tau protein is a microtubule-binding protein that plays an important role in maintaining the structure and function of neuronal cells. However, in neurodegenerative diseases such as Alzheimer's Disease (AD) and a series of other diseases, Tau protein is abnormally phosphorylated and forms neurofibrillary tangles (NFTs), leading to neuronal dysfunction and death. These Tau protein pathological changes are important signs of disease progression. A series of diseases characterized by Tau protein pathological changes are collectively referred to as Tauopathies.

[0003] At present, the detection methods for Tau protein mainly include cerebrospinal fluid (CSF) detection, blood test, magnetic resonance imaging (MRI) and immunohistochemistry. Although CSF detection and blood test provide non-invasiveness and convenience, their sensitivity and specificity still need to be improved, and they cannot provide spatial distribution information of lesions; although MRI can provide detailed images of brain structure, this structural imaging technology has limitations in the detection of early molecular lesions; immunohistochemistry is usually suitable for biopsy sampling or autopsy samples, and has serious deficiencies in detection convenience and real-time monitoring. The above methods provide support for the detection of Tau protein to varying degrees, but they have more or less problems such as strong invasiveness, insufficient sensitivity and specificity, and inability to monitor in real time. Therefore, it is particularly important to develop a method that can sensitively and specifically detect Tau protein in vivo.

[0004] Positron emission tomography (PET) is different from structural imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT). It is a functional imaging technology and a new imaging technology that can display the activities of biological molecular metabolism, receptors, neurotransmitters and other substances in vivo. It is widely used in the diagnosis and differential diagnosis of various diseases, efficacy evaluation, organ function research and new drug development. PET imaging has the characteristics of strong specificity, high sensitivity and excellent penetration. Especially in the early stage of the disease at the molecular level, when the lesion area has not yet shown structural changes, MRI and CT examinations often cannot make a clear diagnosis. PET examination can sensitively detect the location of the lesion and provide patients with three-dimensional imaging information in a non-invasive manner, which is convenient for doctors to carry out quantitative and qualitative follow-up research and diagnosis. This is unmatched by other imaging examinations at present.

[0005] In PET, the core needs to use PET imaging agents, also known as PET probes, PET contrast agents, PET tracers, etc., which refer to substances labeled with radionuclides, which can enter the body and specifically recognize and bind to specific target organs, tissues, enzymes, proteins, receptors, etc. PET probes gather in specific areas of the body, and three-dimensional images are presented with the help of signal acquisition equipment and computer imaging software. The most common PET probe is 18-fluoro-deoxyglucose ([ 18 F]FDG), used for specific imaging of glucose metabolism, is widely used in tumor diagnosis and treatment.

[0006] Therefore, it is crucial to develop specific Tau-targeted PET tracers for the detection of Tau protein, which can provide non-invasive real-time three-dimensional images, accurately reflect the spatial distribution and aggregation state of Tau protein, and provide a powerful means for the early diagnosis, disease course monitoring and treatment evaluation of Tau protein diseases.

[0007] Existing Tau-targeted PET tracers mainly include methylene blue derivatives, quinoline derivatives, and benzothiazole derivatives. For example, the THK series ([ 18 F]THK-5117, 18 F]THK-5351) is a methylene blue derivative that achieves imaging by binding to Tau protein, but has problems of low selectivity and non-specific binding; 18 F]AV-1451 (also known as 18 F]T807) as a quinoline derivative, although it showed good imaging performance in early studies, has problems such as high uptake in brain white matter, nonspecific binding and interference from metabolites; 11C]PBB3, as a benzothiazole derivative, can recognize different conformations of Tau protein, but due to the nucleus 11 The half-life of C is only 20 minutes, which limits its wide application. Although these tracers have achieved Tau protein imaging to a certain extent, they still have limitations such as insufficient selectivity and specificity, poor brain-blood barrier penetration, and poor metabolic stability, which limit their wide clinical application. Therefore, it is particularly important to develop Tau-targeted PET tracers with higher specificity, better brain-blood barrier penetration, and better metabolic stability.

[0008] This patent designs and prepares 18 F-labeled toluene imidazopyridine derivatives ([ 18 F]FENPBM), which can selectively target Tau protein with high affinity and has good blood-brain barrier penetration ability, and has rapid metabolic kinetics, thus being applicable to PET imaging of various types of Tau protein diseases including nervous system diseases. In addition, the present invention [ 18 The radioactive synthesis route of F]FENPBM has the characteristics of high stability and high radioactive yield of radioactive labeling. Its function as a PET imaging agent for selective and specific imaging of Tau protein has been verified through PET imaging of cells and Tau protein model animals. Summary of the invention

[0009] The purpose of the present invention is to develop a nuclide 18 The invention discloses a F-labeled PET imaging agent which specifically targets Tau protein, and provides a method for efficiently preparing the same and application thereof.

[0010] The technical solution of the present invention is as follows:

[0011] We designed a molecule with high affinity and selectivity for Tau protein, N-(2-[ 18 F]fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridin-3-amine ([ 18 F]FENPBM) as a PET tracer:

[0012]

[0013] molecular[ 18 F]FENPBM has been tested and shown to have excellent CB1R affinity and selectivity.

[0014] Its corresponding non-radioactive molecule N-(2-fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridin-3-amine (FENPBM) is used as [ 18The structure of the quality control standard of F]FENPBM after radiosynthesis is:

[0015]

[0016] [ 18 In a preparation method of F]FENPBM, the compound molecule required is called a precursor compound in the PET field, denoted as TsOENPBM, and the molecular structure is:

[0017]

[0018] At the same time, the present invention provides a synthesis process of the precursor compound TsOENPBM, comprising the following steps:

[0019] The molecule TsOENPBM uses 2-bromo-4-fluoropyridine as the starting compound, reacts with 2-[tert-butyl(methyl)silyl]oxy-N-methyl-ethylamine to obtain a crude product, which is purified by column to obtain a white powder product, namely 2-bromo-N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N-methyl-pyridin-4-amine. After purification, it continues to couple with 2-bromo-4-methylaniline to obtain N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N, 8-Dimethyl-pyrido[1,2-a]benzimidazol-3-amine is treated with pyridine hydrofluoride to remove the protecting group to obtain 2-[methyl-(8-methylpyrido[1,2-a]benzimidazol-3-yl)amino]ethanol, which is then reacted with p-toluenesulfonyl chloride to prepare 2-(methyl(8-methylbenzo[4,5]imidazo[1,2-a]pyridin-3-yl)amino)ethyl 4-toluenesulfonate (precursor compound molecule TsOENPBM).

[0020] The present invention also provides a synthesis process of the standard product FENPBM, comprising the following steps:

[0021] 2-Bromo-4-fluoropyridine was used as the starting compound, and reacted with 2-[tert-butyl(methyl)silyl]oxy-N-methyl-ethylamine to obtain a crude product, which was purified by column to obtain a yellow oily product 2-[(2-bromo-4-pyridyl)-methyl-amino]ethanol;

[0022] Reaction of 2-[(2-bromo-4-pyridinyl)-methyl-amino]ethanol with diethylaminosulfur trifluoride to obtain 2-bromo-N-(2-fluoroethyl)-N-methyl-4-pyridinamine;

[0023] 2-Bromo-N-(2-fluoroethyl)-N-methyl-4-pyridinamine was coupled with 2-bromo-4-methylaniline to obtain N-(2-fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridin-3-amine, that is, the standard product FENPBM was obtained.

[0024] The present invention also provides 18 A method for preparing F]FENPBM comprises taking the precursor compound TsOENPBM and 18 F ions, under heating conditions, undergo labeling reaction to obtain the [ 18 F]FENPBM molecule.

[0025] The beneficial effects of the present invention are:

[0026] The present invention designs a radioactive nuclide 18 F-labeled methylbenzimidazolinone pyridine derivative and its preparation method, the compound has the ability to target Tau protein. Tau protein is a microtubule-binding protein closely related to neurodegenerative diseases such as Alzheimer's disease, and abnormal aggregation of Tau protein can cause neuronal dysfunction. The compound designed by the present invention can be used as a PET tracer, which can bind to Tau protein with high specificity in vivo. In addition, the radioactive synthesis route of the present invention has the characteristics of high stability and high radioactive yield of radioactive labeling. The present invention can provide key imaging information in early diagnosis, disease progression monitoring, efficacy evaluation and pathological research, and has broad clinical and research application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The synthetic process roadmap of the precursor TsOENPBM is shown in Figure 2.

[0028] Figure 2 This is the synthetic process map of the standard product FENPBM;

[0029] Figure 3 The NMR spectra and mass spectra of key molecules (a) molecule 3 (b) molecule 6 (c) precursor TsOENPBM (d) molecule 7 (e) molecule 8 (f) standard FENPBM;

[0030] Figure 4 for[ 18 F]FENPBM synthesis reaction formula;

[0031] Figure 5 For FENPBM and [ 18 F] RadioHPLC test results of FENPBM solution after mixing;

[0032] Figure 6 for[ 18 [F] Distribution of FENPBM uptake in the brain regions of SD rats (left) healthy group and (right) AD model rats (60-90 minutes, static scan). The red arrow indicates the location of okadaic acid modeling. DETAILED DESCRIPTION

[0033] In order to make the contents of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings.

[0034] Example 1

[0035] According to a specific example of the present invention, a synthetic route of the precursor TsOENPBM of the present invention is as follows Figure 1 As shown,

[0036] The specific synthesis steps are as follows:

[0037] (1) 2-Bromo-N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N-methyl-pyridin-4-amine (molecule 3)

[0038] 2-Bromo-4-fluoro-pyridine (molecule 1, 5 g, 28.41 mmol, 1 eq), N,N-diisopropylethylamine DIEA (11.02 g, 85.23 mmol, 14.85 mL, 3 eq) and N,N-dimethylformamide DMF (50 mL) were added to a flask, and then 2-[tert-butyl (dimethyl) silyloxy]-N-methyl-ethylamine (molecule 2, 5.92 g, 31.25 mmol, 1.1 eq) was added. The reaction mixture was stirred at 80 ° C for 1 hour. The reaction progress was detected by thin layer chromatography. The mixture was quenched with NH4Cl aqueous solution (50 mL), extracted with ethyl acetate (100 mL), repeated 3 times, and the organic layers were combined and finally washed with saturated brine (50 mL) 4 times, the organic phase was dried over sodium sulfate and filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by column chromatography using silica gel to obtain a purified white powder product (i.e., the compound shown in molecule 3) with a yield of 50%. 1H NMR (400 MHz, CDCl3) δ7.88 (d, J = 6.0 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 6.49 (dd, J = 2.4, 6.0 Hz, 1H), 3.85 (t, J = 5.6 Hz, 2H), 3.53 (t, J = 5.6 Hz, 2H), 3.04 (s, 3H); In addition, a yellow oily product can be obtained by the above column purification, which is a by-product of the reaction.

[0039] (2) N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N,8-dimethyl-pyrido[1,2-a]benzimidazol-3-amine (molecule 5)

[0040] Molecule 3 (2.25 g, 6.52 mmol, 1 eq), 2-bromo-4-methylaniline (molecule 4, 1.21 g, 6.52 mmol, 1 eq), CuI (248.16 mg, 1.30 mmol, 0.2 eq), 1,10-phenanthroline (469.62 mg, 2.61 mmol, 0.4 eq) and Cs2CO3 (8.49 g, 26.06 mmol, 4 eq) were added to a flask, and 22 mL of xylene was added for dissolution. The reaction was stirred at 135 ° C for 24 hours. The reaction was monitored by thin layer chromatography (dichloromethane: DCM = 10: 1). After the reaction, the mixture was filtered, and the filter residue was washed with ethyl acetate (10 mL) and dichloromethane (10 mL). All filtrates were collected and concentrated by rotary evaporation. The concentrated mixture was subjected to preliminary column purification using silica gel chromatography to obtain a yellow oily crude product (1 g, 1.70 mmol, purity 76%) (ie, the compound shown in molecule 5) with a yield of about 26%. LCMS: RT = 0.853 min, [M+H] + = 370.2.

[0041] (3) 2-[Methyl-(8-methylpyrido[1,2-a]benzimidazol-3-yl)amino]ethanol (molecule 6)

[0042] A solution of the crude product of the above molecule 5 (0.9 g, 2.44 mmol, 1 eq) in tetrahydrofuran THF (9 mL) was added to the flask, and pyridine hydrofluoric acid (1.98 g, 19.98 mmol, 1.8 mL, 8.20 eq) was added. The reaction was stirred at 20 ° C for 1 hour. The reaction mixture was dried by rotary evaporation, redissolved in DMSO (3 mL) and MeCN (1 mL), and finally purified by preparative high performance liquid chromatography (C18 column 150×40 mm). After drying, a pink solid product (290 mg, 1.10 mmol) (i.e., the compound shown in molecule 6) was obtained with a yield of 45%.

[0043] 1H NMR (400MHz, MeOD) δ8.67(d,J=8.0Hz,1H),7.84(s,1H),7.47(d,J=8.0Hz,1H),7.34(d,J=8.4Hz,1H),7.14-7.06(m,1 H), 6.69 (s, 1H), 3.86-3.79 (m, 2H), 3.74-3.68 (m, 2H), 3.22 (s, 3H), 2.53 (s, 3H); LCMS: RT=0.595min, [M+H]+=256.1.

[0044] (4) 5-(4-(allyloxy)phenyl)-4-(4-(tert-butoxy)-4-oxobutoxy)-1-(2-chlorophenyl)-1H-pyrazole-3-carboxylic acid ethyl ester (precursor compound molecule TsOENPBM)

[0045] Molecule 6 (140 mg, 548.34 μmol, 1 eq), NaOH (6 M, 2.74 mL, 30 eq) and tetrahydrofuran (10 mL) were added to the flask in sequence, and 4-toluenesulfonyl chloride (313.62 mg, 1.65 mmol, 3 eq) was slowly added under stirring at 0 ° C. After the addition of the raw materials, the reaction was stirred at 0 ° C for 3 hours. The reaction progress was monitored by thin layer chromatography (DCM: MeOH = 10: 1). After the reaction, the mixture was quenched with H2O (10 mL) and extracted with ethyl acetate (20 mL × 2). The organic layers were collected and combined, washed with saturated brine (10 mL), dried over sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude solid. Purification was performed using a preparative thin layer chromatography plate (DCM: MeOH = 10: 1) to finally obtain the target product TsOENPBM (213 mg, 509.74 μmol) with a yield of 93%.

[0046] 1 H NMR (400MHz, DMSO-d6) δ8.58(d,J=7.6Hz,1H),7.85(s,1H),7.64(d,J=8.4Hz,2H),7.43(d,J=8.0Hz,1H),7.22(d,J=8.0Hz,2H),7.18-7.13(m ,1H),6.60(dd,J=2.4,7.6Hz,1H),6.19(d,J=2.4Hz,1H),4.21(t,J=4.8Hz,2H),3.77(t,J=4.8Hz,2H),2.92(s,3H),2.48(s,3H),2.15(s,3H). 13 C NMR (101MHz, DMSO-d6) δ150.21,149.03,144.83,131.85,129.83,128.56,127.79,127. 41,126.10,125.70,116.36,110.36,101.98,89.84,68.10,49.84,38.59,21.24,20.80.

[0047] Example 2

[0048] According to a specific example of the present invention, a synthetic route of the standard compound FENPBM of the present invention is as follows Figure 2 As shown, specifically including the following:

[0049] (1) 2-[(2-bromo-4-pyridyl)-methyl-amino]ethanol (molecule 7)

[0050] Molecule 7 is a by-product in the preparation of molecule 3, that is, a yellow oily product (2.25 g, 6.52 mmol) directly obtained through column purification in the corresponding reaction process, with a yield of 12%.

[0051] 1 H NMR(400MHz, CDCl3) δ7.92(d,J=6.0Hz,1H),6.68(d,J=2.4Hz,1H),6.47(dd,J=2.4,6.0Hz,1H), 3.77(t,J=5.6Hz,2H),3.48(t,J=5.6Hz,2H),3.01(s,3H),0.88-0.83(m,9H),0.03-0.02(m,6H)

[0052] (2) 2-Bromo-N-(2-fluoroethyl)-N-methyl-4-pyridinamine (molecule 8)

[0053] Add molecule 7 (511 mg, 2.21 mmol, 1 eq) and dichloromethane (10 mL) to the flask. Slowly add diethylaminosulfur trifluoride DAST (356.43 mg, 2.21 mmol, 292.16 μL, 1 eq) at -78 °C. Stir the reaction at 0 °C for 2 hours. Use TLC (petroleum ether: ethyl acetate = 1:1) to monitor the progress of the reaction. After the reaction is completed, dilute with water (10 mL) and extract with dichloromethane (20 mL) 3 times. Collect and combine all organic layers, continue to wash with saturated saline (10 mL) 2 times, continue to dry the organic phase with sodium sulfate, filter and concentrate with rotary evaporation to obtain a crude product. The crude product is purified by silica gel column chromatography to obtain a colorless oily product (0.115 g, 493.39 μmol) (i.e., the compound shown in molecule 8), with a yield of 22%.

[0054] 1 H NMR (400MHz, CDCl3) δ7.90(d,J=6.1Hz,1H),6.61(d,J=2.5Hz,1H),6.40(dd,J=6.0,2.5Hz,1H),4.59(t, J=4.9Hz,1H),4.47(t,J=4.9Hz,1H),3.63(t,J=5.0Hz,1H),3.56(t,J=5.0Hz,1H),2.98(d,J=0.6Hz,3H).

[0055] (3) N-(2-fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridin-3-amine (molecule FENPBM)

[0056] Add molecule 8 (0.115 g, 493.39 μmol, 1 eq), 2-bromo-4-methylaniline (100.97 mg, 542.73 μmol, 1.1 eq), CuI (18.79 mg, 98.68 μmol, 0.2 eq), 1,10-phenanthroline (35.57 mg, 197.36 μmol, 0.4 eq) and Cs2CO3 (643.03 mg, 1.97 mmol, 4 eq) to a flask, and add 3 mL of xylene as solvent. Stir the reaction at 135 °C for 24 hours. After the reaction is completed, filter the mixture, wash the filter residue with ethyl acetate (10 mL) and dichloromethane (10 mL) in turn, collect all the filtrate and concentrate it by rotary evaporation. After that, preliminary purification was continued by silica gel column chromatography to obtain 80 mg of crude product, which was further purified by preparative HPLC (C18 column: 150×40 mm) to obtain the target compound FENPBM (19 mg, 73.10 μmol) as a yellow solid with a yield of 15%.

[0057] 1 H NMR (400MHz, MeOD) δ8.57(d,J=7.6Hz,1H),7.77(s,1H),7.44(d,J=8.4Hz,1H),7.30(d,J=8.0Hz,1H),6.94(dd,J=1.6,7.6Hz,1H ), 6.50 (d, J = 1.2Hz, 1H), 4.77-4.71 (m, 1H), 4.65-4.59 (m, 1H), 3.94-3.89 (m, 1H), 3.87-3.82 (m, 1H), 3.18 (s, 3H), 2.52 (s, 3H). 13 C NMR (100MHz, Methanol-d4) δ127.37,126.55,113.46,110.52,103.87,86.83,48.24,48. 03,47.94,47.94,47.81,47.78,47.60,47.57,47.56,47.49,47.39,47.17,46.96,37.92.

[0058] The NMR and mass spectrometry results of the above series of molecules are as follows Figure 3 .

[0059] Example 3

[0060] The precursor TsOENPBM was used for radioactive synthesis. 18 F]FENPBM process route is as follows Figure 4 As shown,

[0061] The main steps of the radiochemical process are:

[0062] Using a cyclotron to bombard target water[ 18 O]H2O, through 18 O(p,n) 18 F reaction produces [ 18 F] fluoride ion. The [ 18 F] fluoride ion. Use eluent (0.48 mL acetonitrile, 0.12 mL ultrapure water, 12 mg cryptand K 222 , 6 mg potassium carbonate) adsorbed on the QMA column [ 18 F] fluoride ions were eluted into the reaction bottle. 0.5 mL of anhydrous acetonitrile was added to the reaction bottle, and then the solution in the reaction bottle was azeotropically evaporated at 110 ° C and 50 mL / min of nitrogen flow for 4 minutes. After that, 1 mL of anhydrous acetonitrile was added twice to repeat the drying process (about 3 minutes each time), and finally a completely dried [ 18 F] fluorine source. Add dry [ 18 F] Add 3 mg of p-toluenesulfonic acid precursor TsOENPBM dissolved in 1.5 mL of anhydrous acetonitrile to the fluorine source and react at 110°C for 5 minutes under closed conditions. After the reaction is completed, cool the reaction bottle to 40°C. Use a pipette to take 5 μL of sample and analyze the components of the crude product solution by analytical radioHPLC. Add 50% acetonitrile aqueous solution to the crude product solution to dilute it to 5 mL, and then use semi-preparative liquid chromatography to purify the radioactive crude product, and monitor the radioactivity changes of the fractions by radioactive probe. The semi-preparative chromatographic column is a Phenomenex Synergi Hydro-RP reverse phase chromatographic column (4 μm, 250×10 mm), the mobile phase A is 1‰ trifluoroacetic acid aqueous solution, the mobile phase B is acetonitrile solvent, the flow rate is 5 mL / min, the detection wavelength is 254 nm, and it is equipped with a radioactive probe.

[0063] The semi-preparative liquid chromatography collected the purified 18 The F]FENPBM fraction was diluted with 40 mL of deionized water and passed through a Sep-Pak C18 column to absorb the tracer. The C18 column was then rinsed with 1 mL of ethanol and 9 mL of 10 mg / mL ascorbic acid saline solution. The resulting PET tracer solution was finally filtered through a 0.22 μm sterile filter membrane into a sterile bottle for later use. The uncorrected yield of radioactivity was between 10% and 30%.

[0064] Will[ 18 The F]FENPBM preparation was mixed with non-radioactive FENPBM and co-injected into analytical radioHPLC for detection. The results were as follows: Figure 5 As shown. The emission peak represents [ 18The difference in retention time between the peaks of F]FENPBM (10.075 min) and FENPBM (10.0 min) represented by the UV peak is within 0.1 min, which indirectly proves that [ 18 F]FENPBM was successfully prepared. And according to the radiation peak integration, it is known that [ 18 The radiochemical purity of [F]FENPBM exceeded 99%.

[0065] Example 4

[0066] In this embodiment, [ 18 The first in vivo experiment of FENPBM, using small animal positron emission tomography / computed tomography (microPET / CT) to obtain [ 18 The distribution of F]FENPBM in the brain of Sprague-Dawley (SD) rats in vivo. At the same time, the tau model mouse constructed with okadaic acid was verified. 18 F] FENPBM specific imaging of tau protein.

[0067] The construction method of the model mouse is as follows:

[0068] First, 10 micrograms of packaged okadaic acid (OA) was dissolved in 100 microliters of saline to prepare 100 ng / microliter OA reagent for AD rat modeling. After weighing the rats, 1.5% sodium pentobarbital was injected intraperitoneally at a dose of 50 mg / kg for anesthesia. After anesthesia, the head hair was shaved using a pet shaver to expose the surgical area. The rat's head was fixed on a stereotaxic instrument so that its head was level with the body. A towel was placed on the base of the locator to ensure that the head and body were level. The surgical area was disinfected with iodine, the scalp was cut along the longitudinal axis of the body, the muscle tissue was separated and electrocoagulation was performed to stop bleeding, and the anterior and posterior fontanelles of the skull were exposed. According to the skull sutures, the anterior and posterior fontanelles were found, the three-dimensional operating arm was moved, the anterior fontanelle was aligned and the Z-axis coordinate was reset to zero, and then the operating arm was moved to the posterior fontanelle tangent position. If the Z-axis reading was within ±0.03 mm, the craniofacial level was considered. According to the stereotaxic atlas of the rat brain, the bregma was used as the reference zero point to locate the right hippocampus. The coordinates were -2.5 mm to the right of the midline of the skull (X axis, ML value), -3.8 mm to the anterior and posterior bregma (Y axis, AP value), and -3.4 mm below the dura mater (Z axis, DV value). The three-dimensional manipulator was moved to mark the target position point on the cranial face. The "cross" manipulator was removed, the cranial drill was clamped and the rotation speed was adjusted, and the hole was opened vertically downward. The cranial drill was removed when there was just a sense of breakthrough. The OA solution was absorbed with a 10-μl Hamilton microinjection needle, fixed on the microinjection pump, and the "cross" manipulator was moved back to the cranial hole. When the needle reached the surface of the cranial hole, the Z axis was zeroed, and it continued to rotate slowly downward until the Z axis reading was -3.4 mm, that is, it reached the right hippocampus. 2.0 μl of OA was slowly injected (0.4 μl / min), and the Hamilton needle was slowly withdrawn after staying for 5 minutes. The cranial hole was sealed with bone wax, the scalp was sutured, the wound was disinfected with iodine, and 20,000 units of penicillin were injected intraperitoneally. The rat was removed, kept warm with a 150-watt incandescent lamp, and returned to the cage after waking up. The AD rats in this OA model induce increased tau protein phosphorylation, thereby simulating the pathological characteristics of Alzheimer's disease.

[0069] from Figure 6 It can be clearly observed that in healthy SD rats, there is a lack of tau protein deposition and the probe uptake in the brain is very low. However, in AD model rats, due to the increase in tau protein phosphorylation, the probe uptake has a specific increase in the modeling site. This further proves that [ 18 F]FENPBM has the ability to specifically bind to and image tau protein, especially in brain regions.

[0070] The above results show that the reported and disclosed [ 18F]FENPBM has high affinity and selectivity for tau protein. When the research target is related to tau protein, it can be used as a PET imaging agent in the fields of disease diagnosis, pathological research, and efficacy evaluation. In addition, it will also have application potential in accelerating research progress or drug development.

Claims

1. A novel PET imaging agent targeting Tau protein, characterized in that: N-(2-[ 18 F]fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridin-3-amine, denoted as [ 18 F]FENPBM, its structural formula is as follows:

2. A standard product of the novel PET imaging agent according to claim 1, characterized in that: It is N-(2-fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridine-3-amine, denoted as FENPBM, and its structural formula is:

3. A precursor compound of the novel PET imaging agent according to claim 1, characterized in that: It is denoted as TsOENPBM, and its molecular structure is:

4. The method for preparing the precursor compound TsOENPBM according to claim 3, characterized in that: These include: 2-Bromo-4-fluoropyridine was used as a starting compound, and reacted with 2-[tert-butyl(methyl)silyl]oxy-N-methyl-ethylamine to obtain a crude product, which was purified by column to obtain a white powder product, 2-bromo-N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N-methyl-pyridin-4-amine; 2-Bromo-N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N-methyl-pyridin-4-amine is coupled with 2-bromo-4-methylaniline (molecule 4) to obtain N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N,8-dimethyl-pyrido[1,2-a]benzimidazol-3-amine; Removing the protecting group of N-[2-[tert-butyl(methyl)silyl]oxyethyl]-N,8-dimethyl-pyrido[1,2-a]benzimidazol-3-amine under the action of pyridine hydrofluoride to obtain 2-[methyl-(8-methylpyrido[1,2-a]benzimidazol-3-yl)amino]ethanol; Finally, 2-[methyl-(8-methylpyrido[1,2-a]benzimidazol-3-yl)amino]ethanol is reacted with p-toluenesulfonyl chloride to prepare 2-(methyl(8-methylbenzo[4,5]imidazo[1,2-a]pyridin-3-yl)amino)ethyl 4-toluenesulfonate, that is, the precursor compound TsOENPBM is obtained.

5. The method for preparing the standard FENPBM according to claim 2, characterized in that: These include: 2-Bromo-4-fluoropyridine was used as the starting compound, and reacted with 2-[tert-butyl(methyl)silyl]oxy-N-methyl-ethylamine to obtain a crude product, which was purified by column to obtain a yellow oily product 2-[(2-bromo-4-pyridyl)-methyl-amino]ethanol; Reaction of 2-[(2-bromo-4-pyridinyl)-methyl-amino]ethanol with diethylaminosulfur trifluoride to obtain 2-bromo-N-(2-fluoroethyl)-N-methyl-4-pyridinamine; 2-Bromo-N-(2-fluoroethyl)-N-methyl-4-pyridinamine was coupled with 2-bromo-4-methylaniline to obtain N-(2-fluoroethyl)-N,8-dimethylbenzo[4,5]imidazo[1,2-a]pyridin-3-amine, that is, the standard product FENPBM was obtained.

6. A method for preparing a novel PET imaging agent targeting Tau protein as claimed in claim 1, characterized in that: Take the precursor compound TsOENPBM and 18 F ions, under heating conditions, undergo labeling reaction to obtain the compound [ 18 F]FENPBM.

7. Use of the PET imaging agent according to claim 1 in the preparation of a Tau protein imaging agent or probe.

Citation Information

Patent Citations

  • Radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound

    CN107108616A

  • Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging diagnosis and photodynamic therapy, and preparation method therefor

    CN111954543A

  • [18F]-labeled imidazopyridine derivatives as PET radiotracers

    CN115968362A

  • Substituted aminopyridine compounds as EGFR inhibitors

    CN117980297A